StockWatch
·
PI Industries · Q2 FY-2027 · PREVIEW

Recovery test after Q4's 39% profit collapse

With profits down sharply last quarter and FII exiting, PI Industries must prove stabilisation on new product traction and margin recovery in Q2.

Q2 FY27 resultsPIINDPI Industries Ltd29 Oct 2026 · 3 min read

The setup: stabilisation or further decline?

PI Industries reported a 39% year-on-year collapse in net profit to ₹200 Cr in Q4 FY26, well below analyst consensus, triggering downgrades across the board. The stock has fallen 57% from all-time highs (₹4,804) and now trades 34% below median analyst targets, raising the stakes for Q2: is this a cyclical trough with recovery underway, or a sign of deeper operational challenges? The September registration of Pioxaniliprole — India's first indigenously discovered insecticide — is a material positive that could reshape long-term growth, but the Street wants proof of margin stabilisation and revenue resilience first.

What to expect in Q2

Revenue

~₹350–370 Cr

on-plan trajectory; depends on formulations mix, pipeline momentum, and pricing realisations

EBITDA margin

18–22%

swing factor — Q4 pressure signals input-cost headwinds or volume deleveraging; recovery here defines tone

Net profit

₹35–45 Cr

watch closely — Q4's ₹200 Cr miss flagged cost pressures; stabilisation vs extension matters

A strong Q2 would show: revenue at or above ₹360 Cr, EBITDA margin recovering to 21%+, net profit ₹40+ Cr, and management commentary confirming early Pioxaniliprole traction. A weak Q2 would signal: revenue below ₹350 Cr, margin further compressed, profit below ₹35 Cr, and no visibility on new-product monetization — extending the downtrend and validating recent FII outflow.

On track with guidance?

Unconfirmed. Management's prior FY27 guidance has not been formally reset post-Q4 decline, though the scale of the miss suggests downside revisions are likely. Q1 FY27 results (announced Aug 11) will set a run-rate baseline, but the Q4 miss raises questions about full-year assumptions. The Pioxaniliprole registration in September is strategically significant — it positions PI as an agrochem innovator in addition to a formulator — but ramp timing and contribution in FY27 remain unclear. Management must articulate: (1) whether Q4 was cyclical or structural, (2) FY27 full-year revenue/margin targets, and (3) Pioxaniliprole ramp schedule and market opportunity.

What the Street says

Since Q1 FY27 — recent filings & events

Corporate actions and regulatory filings since August 11, 2026

Sep 21

Event

Pioxaniliprole registration approved (insecticide, indigenously discovered)

Implication

Material positive — opens new revenue stream; validates R&D capability

Oct 19

Event

PI Foundation incorporation (wholly owned subsidiary, Udaipur)

Implication

Likely CSR/strategic entity; routine filing; no operational impact flagged

Oct 27

Event

Board meeting announcement for Nov 4 result approval

Implication

On schedule; trading window closed Sep 25 (routine); no insider activity flagged

Ownership trends: FII stake fell from 16.97% (Q1 FY26) to 14.83% (Q1 FY27) — a 204 bps outflow on Q4's profit miss and near-term weakness. DII holdings stable at 31.64%. Promoter unchanged at 46.09%. The FII exit underscores caution on near-term earnings recovery.

Key watch items for result day (Nov 4)

Three things that will move the needle
  • 1 · Revenue & margin stabilisation

    Does Q2 show revenue back on trajectory (₹360+ Cr) and EBITDA margin recovery (21%+)? A miss here (₹350 Cr or <18% margin) extends the downtrend and validates FII skepticism. A beat resets sentiment toward the ₹3,020 target.

  • 2 · Pioxaniliprole early traction & ramp visibility

    What are initial sales, market uptake, and full-year contribution expectations? Management's confidence in monetization timeline (Q2, Q3, or delayed?) will drive the long-term narrative. Lack of detail keeps consensus cautious.

  • 3 · FY27 full-year guidance reset

    Will management reaffirm pre-Q4 targets or revise lower? A reset lower validates near-term caution but may unlock upside to FY28 growth. Flat or bullish guidance would support the ₹3,020 consensus; a downside revision extends the HOLD rating.

PI Industries enters Q2 in the doghouse: Q4's 39% profit collapse, FII selling, and a 57% peak-to-trough decline have created a wide credibility gap between the Street's ₹3,020 median target and the stock's ₹2,055 reality. The Pioxaniliprole registration is genuine innovation upside, but it's also a longer-term story — the immediate test is whether the company can stabilise margins, defend revenue, and prove that Q4 was cyclical, not structural. Nov 4 will tell whether this is the inflection point or if further pain awaits.

Informational and educational content only. Not investment advice.